National Cancer Institute, Research Contracts Branch, Purchasing and Support Contracts Section, EPS/638, 6120 EXECUTIVE BLVD MSC 7228 BETHESDA MD 20892-7228

65 -- SUCROSE PURIFIED HIGH TITER VACCINIA VIRUS SOL N02-CB-56208-84 POC Eileen Keating Carnaggio, Contract Specialist or Janet Mattson, Contra cting Officer 301/402-4509. The National Cancer Institute plans to procure on a SOLE SOURCE basis under authority of FAR 6.320-1, in accordance with 41 U.S.C. 253(c)(1), the production of High Titer Recombinant Vaccinia Virus in HeLa S3 Spinner Cultures, Purification and Concentration over Sucrose, Tissue Culture Infected Dose (TDIC) 50 and Electron Microscope (EM) Virus Particle Count from Advanced Biotechnologies, Inc., Rivers Park II, 9108 Guilford Rd., Columbia, MD 21046. The items are for the Laboratory of Immunology and Biology (LTIB), for use in an ongoing research project. The primary service required of the vendor includes the propagation of high titer recombinant vaccinia virus in HeLa S3 spinner cultures, purification over sucrose, concentration of the virus to 1 x 1010 Plaque Forming Units (PFU)/ml., TCID 50 and EM titer verification. The custom growth of recombinant vaccinia virus in HeLa S3 spinner cultures is the only way NCI can achieve the high titers of virus propagation and purification necessary. The LTIB requires delivery of the high titer virus within three to four weeks from the date virus inoculum is picked up by the contractor. The LTIB began using the services of Advanced Biotechnologies, Inc. (ABI) in 1991 for the production and purification of vaccinia virus. Several other vendors were contacted but none were willing to grow the virus except ABI. In 1994, LTIB tested the services of another vendor. The virus preparation took over six weeks to produce and the total plaque forming units of virus they were capable of delivering using roller bottle cultures was 80% less than with spinner cultures. In addition, they did not have the capability of validating the virus using electron microscopy particle counts. The LTIB requires delivery of the high titer virus within three-four weeks from the date the LTIB recombinant virus is picked up by the contractor. A change in vendors at this time would be detrimental to the LTIB program for the development of novel recombinant pox virus therapies for the treatment of cancer. The LTIB does not wish to introduce new variables into the ongoing experiments and especially do not wish to cause delays generated by the introduction of the services of a new vendor. To introduce a new vendor at this time would be very costly and would not be in the best interest of the Government since it would delay the development of these novel new therapies for the treatment of human carcinomas. The planned period of performance is 12 months plus 4 successive 12-month periods. Due to the above requirements and the unique capabilities of ABI, there is no other known vender to meet NCI's requirements. It is the Government's belief that the above requirements can only be met by ABI. This notice of intent is not a request for competitive proposals, however, if an interested party believes they can meet the above specifications, they may submit a statement of capabilities. Information furnished shall include enough material, in sufficient detail, to perform a proper evaluation of their ability to perform. Closing date is 45 days after publication of this notice. SEE Note 22. (0121)

Loren Data Corp. http://www.ld.com (SYN# 0323 19950502\65-0001.SOL)